


Enhancing patient safety with tomorrow's logistics

Andreas Koch

Head of Wholesale & Logistics

Galenica Investor Day 2023

Three fields of action




Modernisation



Efficiency



Sustainability



Wholesale & Logistics modernisation projects: where we stand today



Distribution center in Ecublens
reopened in September 2022

Verkaufsbeleg Bearbeiten Springen Zusätze Umfeld System Hilfe

Modulo

Position 10 Positionstyp ZG70 G: Lagerware
Material 2010086243 BUSCOPAN Supp 10 mg 6 Stk


Verkauf A Verkauf B Versand Faktura **Konditionen** Kontierung Einstellungen Partner Note Bestelldaten Status Struktur Zusatzdat

Menge 3 ST Netto 57.01 CHF Steuer 1.43

Konditionssatz Analyse Aktualisieren

Preis	KArt	Bezeichnung	Betrag	Währ	pro	ME	Konditionswert	Währ	Status	KUmZä	ATO/MTS	Component
	ZGPC	Listenpreis	6.90	CHF	1	ST	20.70	CHF			1	
	ZGPF	EP1	6.90	CHF	1	ST	20.70	CHF			1	
	ZGPE	EP2	6.90	CHF	1	ST	20.70	CHF			1	
	ZGES	BP Galaxis	7.62	CHF	1	ST	22.86	CHF			1	
		BP Galaxis	6.90	CHF	1	ST	20.70	CHF			1	
	ZGDD	Direktlieferung	7.000	€			1.45	CHF			0	
		Best Direkt vs. PSM	0.49	CHF	1	ST	1.45	CHF			1	
		Best Direkt / PSM vs	7.38	CHF	1	ST	22.15	CHF			1	
		Best Fix vs. Direkt	7.38	CHF	1	ST	22.15	CHF			1	
		Referenzpreis	7.38	CHF	1	ST	22.15	CHF			1	
	ZGDG	E % auf EP2 abzgl RP	20.000	€			4.14	CHF			0	


Modulo making significant strides:
Over 90% of partners migrated by
Alloga; go-live of Galaxis Ecublens in
summer '24 and Niederbipp '25



Benefits of Modulo

Previous systems were outdated

Staff to maintain the systems can hardly be found



«Paperless Picking» on the shop floor

Harmonised and up-to-date processes

Optimised allocation of articles, also in case of shortages or special orders

Digital backbone for future growth



Innovating and simplifying our fleet



- Electric pilot vehicle being tested
- Already two biogas transporters in daily use
- Strategic cooperations lead to reduced number of external transportation partners, which results in lower complexity



Creating sustainable logistics



Solar panels on facilities in Burgdorf, Ecublens and Niederbipp



Testing of alternative drive systems with strong focus on sustainability



Sustainability: more than eco-friendly operations

INITIATIVE SAFETY STOCK

- Joint initiative Safety Stock with Sandoz
- Greatly increasing the national safety stocks of generic medicines
- Enabling treatment of chronic diseases to bridge possible supply shortages in Switzerland

Disclaimer

Disclaimer Galenica

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.

Disclaimer IQVIA © 2022, IQVIA AG

All rights reserved. The information may not be duplicated, stored, processed further, nor be made accessible in whole or in part to any third party without prior express and valid written permission of IQVIA AG. Terms used in connection with data/figures such as „patient“, „doctor“, „medical practice“, „prescriber“, or „pharmacy“ do not designate any personal data but exclusively anonymous information (according to applicable, valid data protection laws).

IQVIA utilizes highly sophisticated technologies and methods in order to ensure that all its Information Services meet the applicable data protection requirements, regardless of the way data are combined.